Multiple Myeloma an incurable disease, but I have spent the last 25 years in remission using a blend of conventional oncology and evidence-based nutrition, supplementation, and lifestyle therapies from peer-reviewed studies that your oncologist probably hasn't told you about.
Click the orange button to the right to learn more about what you can start doing today.
“We aimed to clarify the therapeutic effects on Multiple Myeloma cells and their progenitors by hyperthermia. Heat treatment at 43°C time-dependently induced MM cell death.”
Whole-body hyperthermia (WBH) is too good to be true. It is the ultimate lifestyle therapy. At least it may be for multiple myeloma patients and survivors. I say this because research shows that
I am not saying that WBH will cure your multiple myeloma. I’m saying that cancer coaching since 2015 has taught me that neither conventional (traditional) therapies nor evidence-based non-conventional therapies alone will give you the combination of quality and quantity of life that you are searching for.
Most MM patients need induction therapy (RVd-D) in order to stabilize their incurable blood cancer. And it is those same myeloma patients who undergo 2,4,6 etc. cycles of induction therapy that need to enhance their immune function while weakening their monoclonal stem cells with whole-body hyperthermia.
The six blog posts that talk about WBH linked below explain the ins and outs of this non-conventional myeloma therapy. Let me know what you think.
“Multiple myeloma (MM) remains incurable, and MM-initiating cells or MM progenitors are considered to contribute to disease relapse through their drug-resistant nature. In order to improve the therapeutic efficacy for MM, we recently developed novel superparamagnetic nanoparticles which selectively accumulate in MM tumors and extirpate them by heat generated with magnetic resonance.
We here aimed to clarify the therapeutic effects on MM cells and their progenitors by hyperthermia. Heat treatment at 43°C time-dependently induced MM cell death.
The treatment upregulated endoplasmic reticulum (ER) stress mediators, ATF4 and CHOP, while reducing the protein levels of Pim-2, IRF4, c-Myc and Mcl-1. Combination with the proteasome inhibitor bortezomib further enhanced ER stress to potentiate MM cell death. The Pim inhibitor SMI-16a also enhanced the reduction of the Pim-2-driven survival factors, IRF4 and c-Myc, in combination with the heat treatment. The heat treatment almost completely eradicated “side population” fractions in RPMI8226 and KMS-11 cells and suppressed their clonogenic capacity as determined by in vitro colony formation and tumorigenic capacity in SCID mice. These results collectively demonstrated that hyperthermia is able to impair clonogenic drug-resistant fractions of MM cells and enhance their susceptibility to chemotherapeutic drugs.